Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2010-06-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- Magnetic resonance imaging (MRI) scans must be performed according to specified sets of parameters that provide optimal images of each organ and each area of the body. These scanning parameters are often specific to the institution or organization at which they are employed, and may also depend on the manufacturer of the MRI scanning equipment. Because MRI scanning equipment is always being updated and upgraded, researchers are interested in developing new and optimized scanning parameters for MRI scans.
Objectives:
\- To improve current methods and develop new techniques for magnetic resonance imaging.
Eligibility:
* Individuals 18 years of age and older who are either volunteers or current NIH protocol participants.
* Participants must not have any medical history factors (e.g., extreme claustrophobia, history of metal implants) that would prevent them from receiving MRI scans.
Design:
* Participants will have at least one MRI scan that will last from 20 minutes to 2 hours (most scans will last between 45 and 90 minutes). The total time commitment for most visits will be approximately 4 hours from start to finish.
* Some MRI techniques require standard monitoring equipment or specific procedures during the scanning, such as an electrocardiogram.
* Participants will have blood samples taken at the time of the scan. Some MRI studies will require the use of a contrast agent that will be administered during the scan.
* Volunteers may be asked to return for additional MRI scans over the course of a few years. Follow-up scans may be done on the same part of the body or on different parts of the body. No more than one MRI scan will be performed in any 4-week period for this protocol....
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Volunteers
Volunteers (maybe Volunteers, NIH employee and current NIH protocol participants)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
B. Lab Eligibility parameters (for contrast scans within 4 weeks of gadolinium injection):
C. Creatinine below upper normal limit
D. eGFR \>= 60 mL/min/1.73m2
E. Age \>= 60 or history of renal disease: test GFR within 1 week prior to contrast
F. Willing to travel to the NIH for follow-up visits.
G. 18 years old
H. Able to understand and sign informed consent
I. No MRI scan with gadolinium injection in the last 6 months under this protocol.
Exclusion Criteria
* Aneurysm clip, implanted neural stimulator,
* Implanted cardiac pacemaker, defibrillator, or certain other implanted electrical or metallic devices,
* Cochlear implant, ocular foreign body (metal shavings),
* Any implanted device (pumps, infusion devices, etc.),
* Shrapnel injuries,
* History of metal in head or eyes or other parts of the body.
B. Pregnant women
C. Paralyzed hemidiaphragm
D. Over 500 lbs and/or a body circumference that prevents the study subject from laying flat in the scanner
E. Surgery of uncertain type
F. Untreatable claustrophobia otherwise requiring anesthesia.
G. Any contraindications that the Physician identifies from the subject, MRI Safety Questionnaire, and/or History and Physical.
EXCLUSION FOR PARTICIPANTS FOR GADOLINIUM CONTRAST:
A. Allergy to gadolinium for scans using contrast; will be eligible for non-contrast scans.
B. Acute renal failure, renal transplant, dialysis and renal failure individuals (eGFR \<60 mL/min/1.73m2 and/or clinically diagnosed).
C. Individuals with a history of liver transplant or severe liver disease.
D. Lactating women
E. Individuals with hemoglobinopathies or severe asthma.
F. Patient preference to not undergo intravenous line placement and/or receive gadolinium contrast. Contrast administration is optional and participants may still undergo a non-contrast study.
G. GBCA with an MRI scan in the last 6 months. This includes scan performed with GBCA at any outside institution and / or at the clinical center .In addition, they cannot have reached their maximum of 4 GBCA imaging studies under this protocol. They will be excluded from having a contrast enhanced MRI, but will not be excluded from the protocol for non-contrast MRI studies.
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health Clinical Center (CC)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bernadette A Redd, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institutes of Health Clinical Center (CC)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Mattay VS, Weinberger DR, Barrios FA, Sobering GS, Kotrla KJ, van Gelderen P, Duyn JH, Sexton RH, Moonen CT, Frank JA. Brain mapping with functional MR imaging: comparison of gradient-echo--based exogenous and endogenous contrast techniques. Radiology. 1995 Mar;194(3):687-91. doi: 10.1148/radiology.194.3.7862963.
Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Radiology. 2009 Feb;250(2):371-7. doi: 10.1148/radiol.2502080498.
Frank JA, Mattay VS, Duyn J, Sobering G, Barrios FA, Zigun J, Sexton R, Kwok P, Woo J, Moonen C, et al. Measurement of relative cerebral blood volume changes with visual stimulation by 'double-dose' gadopentetate-dimeglumine-enhanced dynamic magnetic resonance imaging. Invest Radiol. 1994 Jun;29 Suppl 2:S157-60. doi: 10.1097/00004424-199406001-00052. No abstract available.
Ahlman MA, Raman FS, Penzak SR, Pang J, Fan Z, Liu S, Gai N, Li D, Bluemke DA. Part 1 - Coronary angiography with gadofosveset trisodium: a prospective feasibility study evaluating injection techniques for steady-state imaging. BMC Cardiovasc Disord. 2015 Dec 22;15:177. doi: 10.1186/s12872-015-0176-0.
Raman FS, Nacif MS, Cater G, Gai N, Jones J, Li D, Sibley CT, Liu S, Bluemke DA. 3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging. 2013 Jun;29(5):1085-94. doi: 10.1007/s10554-013-0192-z. Epub 2013 Mar 21.
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-CC-0115
Identifier Type: -
Identifier Source: secondary_id
100115
Identifier Type: -
Identifier Source: org_study_id